Airway Progenitor/Stem Cells for Treatment of Pulmonary Disorders and Lung Allografts
- Detailed Technology Description
- Researchers at Nationwide Children’s Hospital are developing a novel therapy where airway progenitor/stem cells are collected and then administered to patients with pulmonary disorders and lung transplants.
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
Progressive lung diseases such as cystic fibrosis, primarily ciliary dyskinesia, idiopathic pulmonary fibrosis and few others have no cure, with many of these patients requiring lung transplants. Even after transplant, these patients can develop chronic lung allograft dysfunction, commonly in the form of bronchiolitis obliterans syndrome, which leads to the need for another lung transplant or death. With no cure, cell therapy could make a significant impact on numerous pulmonary diseases and allograft complications. Researchers at Nationwide Children’s Hospital are developing a novel therapy where airway progenitor/stem cells are collected and then administered to patients with pulmonary disorders and lung transplants.
- *Inquiry
- Kyle Murrah, Ph.D. The Research Institute at Nationwide Children's Hospital Office of Technology Commercialization 700 Children's Drive Columbus OH 43205 T: 614 355-4551 F: 614 722-2716 Kyle.Murrah@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
For more information, please click Here
